{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/giant-cell-arteritis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field f3b35a7d-398f-490f-8043-b05b323687d1 --><h2>Changes</h2><!-- end field f3b35a7d-398f-490f-8043-b05b323687d1 -->","summary":null,"htmlStringContent":"<!-- begin item 770fc8eb-df86-40cd-b0bb-9644bc4c016a --><!-- begin field 89183a1c-2d20-4102-950b-345f21a7917a --><p><strong>September 2020</strong> — reviewed. A literature search was conducted in August 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. One NICE quality standard was added to the topic. No major changes to recommendations have been made.</p><!-- end field 89183a1c-2d20-4102-950b-345f21a7917a --><!-- end item 770fc8eb-df86-40cd-b0bb-9644bc4c016a -->","topic":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90","topicId":"922f2e2a-90b2-4d8e-8df9-97f686e2dd9c","topicName":"Giant cell arteritis","slug":"giant-cell-arteritis","lastRevised":"Last revised in September 2020","chapters":[{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ffc44fb-e6ab-5564-afaf-41f6ec23ae59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes"},{"id":"b6663d8f-4d43-5493-b6ea-21be0eeae0f0","slug":"update","fullItemName":"Update"}]},{"id":"fbf9fbe8-db19-571e-9da9-58c8a33c3a25","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4a198ad6-17e2-5c80-a074-90f34f9ef1b7","slug":"goals","fullItemName":"Goals"},{"id":"a77ffdda-deba-58f0-9fec-65219eeb836f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0979f67-3177-527b-add9-89f384b45f07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c79d9855-b433-5fba-b27d-0999158ea93d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"941fce5c-cd66-5a8b-94ed-bcdf176a7c54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e4b575e0-3a70-5c29-afb2-b56f7ba46307","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ea4258e9-d463-5d81-ac84-d12cda80042f","slug":"definition","fullItemName":"Definition"},{"id":"cfe98d94-f2b6-58e5-828a-449fb49d3b2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications"},{"id":"0c5a3725-06fd-5f2f-8aae-4f12da09ec7d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis"},{"id":"e8c3752d-f9fb-5624-a000-60653edb83ac","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","fullItemName":"Management","slug":"management","subChapters":[{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"}]},{"id":"5a8fb527-3c07-5253-86eb-d10fc0d5b656","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ff1b1a4d-96ab-5f26-82ea-b4b059ac602f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"627bf4b4-8b65-59ac-8e48-1f7ac20afa3c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"403ae553-2865-56af-9e95-a012c674b4de","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17c8d522-4e76-5f45-aa32-83ed694272f1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bb85fa5d-a667-5361-b411-a3837f26bdc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1f292226-0f24-56c9-983b-c8fa1738c13f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e1a018ae-4d22-516e-8a99-d688c0d3dda6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"43b25ec9-07b2-5d0e-8fac-20da9cab6506","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field b569fa62-572b-4bcb-9644-fe44c58b2af2 --><h3>Previous changes</h3><!-- end field b569fa62-572b-4bcb-9644-fe44c58b2af2 -->","summary":null,"htmlStringContent":"<!-- begin item 2047fe19-d692-40b6-8996-dc1b1d47131b --><!-- begin field 3ee63194-2233-43f9-8d70-f7dc04a818fe --><p><strong>March 2020</strong> — reviewed. A literature search was conducted in March 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The diagnosis and management sections have been updated in line with the British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020b</a>].</p><p><strong>July 2014 </strong>— reviewed. A literature search was conducted in February 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The diagnosis and management sections have been restructured, and minor changes have been made to the recommendations in the section on monitoring to reflect that a more flexible approach may be an option in primary care compared with secondary care.</p><p><strong>February 2014 </strong>— minor update. The prescribing information on systemic corticosteroids has been deleted and replaced with a link to the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</p><p><strong>February 2010 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>June 2010 </strong>— minor update to include new advice from the British Society for Rheumatology regarding their suggested tapering regimen for prednisolone. Issued in June 2010.</p><p><strong>July 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and proton pump inhibitors. Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential. Issued in July 2009.</p><p><strong>December 2008 to May 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Together with the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polymyalgia-rheumatica/\">Polymyalgia rheumatica</a>, this CKS topic replaces the former topic on <em>PMR and GCA. </em>There has been one major change to the recommendations. Low-dose aspirin is now recommended.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued September 2008.</p><p><strong>July 2006 </strong>— minor update to include the Commission on Human Medicine's warning for bisphosphonates and associated osteonecrosis of the jaw. Issued in July 2006.</p><p><strong>June 2005 </strong>— reviewed. Validated in September 2005 and issued in November 2005.</p><p><strong>January 2004 </strong>— updated to incorporate the safety update from the Committee on Safety of Medicines (CSM) advising that hormone replacement therapy (HRT) should no longer be used first-line for the prevention of osteoporosis. Issued in February 2004.</p><p><strong>June 2003 </strong>— updated to incorporate new guidance from the Royal College of Physicians: <em>Glucocorticoid-induced osteoporosis</em>. Validated in September 2003 and issued in October 2003.</p><p><strong>January 2002 </strong>— reviewed. Validated in March 2002 and issued in April 2002.</p><p><strong>June 1999 </strong>— written. Validated in October 1999 and issued in January 2000.</p><!-- end field 3ee63194-2233-43f9-8d70-f7dc04a818fe --><!-- end item 2047fe19-d692-40b6-8996-dc1b1d47131b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}